Beta Drugs- Standalone HY2-FY21 Net profit rises to Rs. 3.91 crore against Rs. 3.09 crore in HY2-FY20

Beta Drugs – Standalone HY2-FY21 Revenue reached Rs.44.97 crore against Rs. 31.38 crore in HY2-FY20.

Beta Drugs- CONSOL HY1-FY21 PAT jumps to Rs.5.18 crore against PAT of Rs.5.12 crore in HY1-FY20.

Beta Drugs- Standalone HY1-FY21 PAT of Rs.3.06 crore against of profit Rs.4 crore in HY1-FY20.

Standalone PAT of Rs.3.09 crore at Beta Drugs in HY2 FY19-20

Beta Drugs announced its standalone and consolidated financial results for the half year ended on March 31, 2020.

Uzbekistan Plant of Beta Drugs gets manufacturing license

Beta Drugs to become the world‘s first company to manufacture oncology drugs in Uzbekistan.

Beta Drugs made a profit growth of 5 Lakh approximately

Beta Drugs announced the standalone and consolidated financial results of the year that ended on 31st March, 2019.

Beta Drugs approved Rs. 5 crore preferential share issue to Suryavanshi Commotrade

A dedicated leader in Oncology Formulation development activities, Beta Drugs Limited issued 6,45, 244 equity shares of the company to Suryavanshi Commotrade Pvt Ltd, a Kolkata based company.

Beta Drugs turns Investor for Subsidiary Adley Formulations

Beta Drugs got the approval for investing in wholly owned subsidiary of the company.